Publications

Export 74 results:
Author Title Type [ Year(Asc)]
Filters: Author is Serge Gauthier  [Clear All Filters]
2017
Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedet AL, Shin M, Kang MSu, Li X, Ba M, Kandiah N et al..  2017.  Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 88(19):1814-1821.
Ba M, Li X, Ng KPin, Pascoal TA, Mathotaarachchi S, Rosa-Neto P, Gauthier S.  2017.  The prevalence and biomarkers' characteristic of rapidly progressive Alzheimer's disease from the Alzheimer's Disease Neuroimaging Initiative database.. Alzheimers Dement (N Y). 3(1):107-113.
Gauthier S, Robillard J, de Champlain J.  2017.  Progress in transnational scientific and ethics review: Commentary on the proposal for a single North American review board for research on dementia.. Alzheimers Dement.
Schoemaker D, Mascret C, D Collins L, Yu E, Gauthier S, Pruessner JC.  2017.  Recollection and familiarity in aging individuals: Gaining insight into relationships with medial temporal lobe structural integrity.. Hippocampus. 27(6):692-701.
Gauthier S.  2017.  Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue.. Expert Rev Neurother. 17(1):1-2.
Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, Beaudry T, Kang MSu, Soucy J-P, Labbe A et al..  2017.  Synergistic interaction between amyloid and tau predicts the progression to dementia.. Alzheimers Dement. 13(6):644-653.
Müller WE, Eckert A, Eckert GP, Fink H, Friedland K, Gauthier S, Hoerr R, Ihl R, Kasper S, Möller H-J.  2017.  Therapeutic efficacy of the Ginkgo special extract EGb761(®) within the framework of the mitochondrial cascade hypothesis of Alzheimer's disease.. World J Biol Psychiatry. :1-17.
Savaskan E, Mueller H, Hoerr R, von Gunten A, Gauthier S.  2017.  Treatment effects of Ginkgo biloba extract EGb 761® on the spectrum of behavioral and psychological symptoms of dementia: meta-analysis of randomized controlled trials.. Int Psychogeriatr. :1-9.
2016
Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung C-O, Shin M, Wang S, Beaudry T, Kang MS, Soucy J-P et al..  2016.  Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease.. Mol Psychiatry.
Ba M, Kong M, Li X, Ng KPin, Rosa-Neto P, Gauthier S.  2016.  Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener. 5:20.
Laforce R, Rosa-Neto P, Soucy J-P, Rabinovici GD, Dubois B, Gauthier S.  2016.  Canadian Consensus Guidelines on Use of Amyloid Imaging in Canada: Update and Future Directions from the Specialized Task Force on Amyloid imaging in Canada.. Can J Neurol Sci. 43(4):503-12.
Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H et al..  2016.  Defeating Alzheimer's disease and other dementias: a priority for European science and society.. Lancet Neurol. 15(5):455-532.
Gordon MForrest, Lenderking WR, Duhig A, Chandler J, J Lundy J, Miller DS, Piault-Louis E, Doody RS, Galasko D, Gauthier S et al..  2016.  Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase.. Alzheimers Dement. 12(1):75-84.
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.  2016.  Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Schoemaker D, Buss C, Head K, Sandman CA, Davis EP, M Chakravarty M, Gauthier S, Pruessner JC.  2016.  Hippocampus and amygdala volumes from magnetic resonance images in children: Assessing accuracy of FreeSurfer and FSL against manual segmentation.. Neuroimage. 129:1-14.
Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K et al..  2016.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.. Alzheimers Dement. 12(3):292-323.
Schoemaker D, Poirier J, Escobar S, Gauthier S, Pruessner J.  2016.  Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MSu, Beaudry T, Fonov VS, Gauthier S, Labbe A et al..  2016.  VoxelStats: A MATLAB Package for Multi-Modal Voxel-Wise Brain Image Analysis.. Front Neuroinform. 10:20.
Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton LT.  2016.  Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12(1):60-4.

Pages


  • Douglas Hospital
  • Dobell Pavillion
  • Brain imaging centre